These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37903486)

  • 1. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
    Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Iwasaki T; Takenaga N; Kasahara Y; Ouchi K; Shirota H; Takahashi M; Ishioka C
    Oncology; 2024; 102(5):359-367. PubMed ID: 37903486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
    Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
    Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
    Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
    J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
    Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
    Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
    Honma Y; Nagashima K; Hirano H; Shoji H; Iwasa S; Takashima A; Okita N; Kato K; Boku N; Murakami N; Inaba K; Ito Y; Itami J; Kanamori J; Oguma J; Daiko H
    Cancer Med; 2020 Jan; 9(2):595-604. PubMed ID: 31794158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus.
    Katada C; Komori S; Yoshida T; Kawakami S; Watanabe A; Ishido K; Azuma M; Wada T; Hosoda K; Yamashita K; Hiki N; Tanabe S; Ishiyama H; Koizumi W
    Esophagus; 2020 Apr; 17(2):135-140. PubMed ID: 31321580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
    Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T
    Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
    Lamarca A; Frizziero M; Barriuso J; McNamara MG; Hubner RA; Valle JW
    Clin Transl Oncol; 2019 Jul; 21(7):950-953. PubMed ID: 30506132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
    McGarrah PW; Leventakos K; Hobday TJ; Molina JR; Finnes HD; Westin GF; Halfdanarson TR
    Pancreas; 2020 Apr; 49(4):529-533. PubMed ID: 32282766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.
    Lee SM; James LE; Qian W; Spiro S; Eisen T; Gower NH; Ferry DR; Gilligan D; Harper PG; Prendiville J; Hocking M; Rudd RM
    Thorax; 2009 Jan; 64(1):75-80. PubMed ID: 18786981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer.
    Sculier JP; Lafitte JJ; Lecomte J; Berghmans T; Thiriaux J; Van Cutsem O; Efremidis A; Ninane V; Paesmans M; Mommen P; Klastersky J;
    Ann Oncol; 2002 Sep; 13(9):1454-9. PubMed ID: 12196372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
    Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T
    Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD; Spigel DR; Litchy S; Greco FA
    J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.